AstraZeneca announced Thursday that patients in a trial who received its immunotherapy Imfinzi before and after surgery had considerably longer progression-free survival than those given chemotherapy.
The patients in the late-stage study had resectable, early-stage non-small cell lung cancer. They were either treated with chemotherapy before surgery or with Imfinzi as monotherapy after surgery.
AstraZeneca reported that Imfinzi was well tolerated and that there were no new safety concerns with the drug before or after surgery.
Reuters Health also covered the news on Twitter:
Lung cancer patients treated with AstraZeneca's immunotherapy Imfinzi pre- and post-surgery in a trial lived significantly longer without the disease progressing or recurring than those treated with chemotherapy, the drugmaker said on Thursday. https://t.co/v0MLI15P6d
— Reuters Health (@Reuters_Health) March 9, 2023
As of December, AstraZeneca reported that the medicine has failed to meet the primary objective of a trial in patients with advanced lung cancer.
Patients with non-small cell lung cancer who had tumor cells that exhibited high amounts of PD-L1 were examined in that late-stage study using Imfinzi as a monotherapy against platinum-based chemotherapy.
You can also follow us on our official account on Twitter to stay in touch with us.
Read the post below if you’re interested in learning more news:
- A Rally In Philadelphia Has Been Planned In Response To The Texas Abortion Ban Lawsuit
- 2 Americans Kidnapped In Mexico Were Discovered Dead, 2 Returned To US Alive
